SEC Company Response from AXCAN PHARMA INC (CIK 0001116094) — Sep 21, 2005
AXCAN PHARMA INC (CIK 0001116094)
Date: Sept. 21, 2005 · CIK: 0001116094 · Accession: 0001116679-05-002346
AI Filing Summary & Sentiment
File numbers found in text: 000-30860
Letter
Via EDGAR Confidential Treatment Requested by Axcan Pharma Inc. Under 17 C.F.R. Section 200.83 September 21, 2005 Securities and Exchange Commission Judiciary Plaza 100 F Street, N.W. Washington, DC 20549 Attention: Filing Desk
RE: Axcan Pharma 40-F for the fiscal year ended September 30, 2004 File No. 000-30860
Dear Sirs,
Axcan Pharma Inc. ("Axcan" or the "Company") is pleased to submit the following reply to the request for additional information given comments raised in Donald Abbott's voice messages of August 16, 2005 (the "2nd Request for Comments") regarding Axcan's 40-F filing for the fiscal year ended September 30, 2004 and its response of August 3, 2005 to the comments raised in your July 6, 2005 letter ("Comment Letter"). The individual responses of the Company to each of the Commission's comments are set forth below, together with the related requests. The headings and numbers of the responses coincide with the headings and requests numbers set forth in the 2nd Request for Comments.
Confidential Treatment Requested by the Company [C1].
Sincerely,
/s/ Jean Vezina
Show Raw Text
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
Via EDGAR Confidential Treatment
Requested by Axcan Pharma Inc.
Under 17 C.F.R. Section 200.83
September 21, 2005
Securities and Exchange Commission
Judiciary Plaza
100 F Street, N.W.
Washington, DC 20549
Attention: Filing Desk
RE: Axcan Pharma
40-F for the fiscal year ended September 30, 2004
File No. 000-30860
Dear Sirs,
Axcan Pharma Inc. ("Axcan" or the "Company") is pleased to submit the following
reply to the request for additional information given comments raised in Donald
Abbott's voice messages of August 16, 2005 (the "2nd Request for Comments")
regarding Axcan's 40-F filing for the fiscal year ended September 30, 2004 and
its response of August 3, 2005 to the comments raised in your July 6, 2005
letter ("Comment Letter"). The individual responses of the Company to each of
the Commission's comments are set forth below, together with the related
requests. The headings and numbers of the responses coincide with the headings
and requests numbers set forth in the 2nd Request for Comments.
Confidential Treatment Requested by the Company [C1].
Sincerely,
/s/ Jean Vezina
Jean Vezina
Vice President, Finance and Chief Financial Officer
</TEXT>
</DOCUMENT>